24/7 Market News Snapshot 26 December, 2024 – Hoth Therapeutics, Inc. Common Stock (NASDAQ:HOTH)

DENVER, Colo., 26 December, 2024 (247marketnews.com) – (NASDAQ:HOTH) are discussed in this article.
Hoth Therapeutics, Inc. is experiencing positive momentum in pre-market trading, with shares currently at $0.800, a rise of 1.65% from the previous close of $0.787. Trading volume has reached 6.80 million shares, reflecting increased investor interest and potential accumulation in the stock. Analysts note that key resistance levels are identified around $0.820 and support at $0.770, indicating that sustaining this upward trend could signal a favorable outlook for the company in the forthcoming sessions.

In a significant development, Hoth Therapeutics has announced an exclusive patent license agreement with the U.S. Department of Veterans Affairs and Emory University. This agreement grants Hoth exclusive rights to a novel patent portfolio focused on Glial Cell Line-Derived Neurotrophic Factor, obesity, and associated health conditions. This strategic collaboration highlights Hoth’s commitment to innovating solutions for obesity and related diseases, aiming to enhance treatment protocols and improve patient outcomes.

Robb Knie, CEO of Hoth Therapeutics, expressed enthusiasm about the partnership, emphasizing the potential of bringing cutting-edge technology to the market. He stated, “This agreement not only marks a pivotal moment in our mission to tackle obesity-related health issues but also reinforces our commitment to science-driven solutions that benefit patients globally.”

Furthermore, Hoth Therapeutics is actively expanding its intellectual property portfolio, planning to secure additional provisional patent protection for its lead therapeutic candidate, HT-001, which targets the oncology sector. This focus on strategic partnerships and innovation underscores Hoth Therapeutics’ mission to propel scientific discoveries into valuable therapeutic solutions, continually striving to address unmet medical needs and advance healthcare technology for better patient outcomes.

Related news for (HOTH)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.